These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8968472)

  • 21. Lipid complexes of amphotericin B: the competitive picture.
    Richardson MD
    J Med Microbiol; 1997 Mar; 46(3):185-7. PubMed ID: 9126817
    [No Abstract]   [Full Text] [Related]  

  • 22. Amphotericin B toxicity reduced by administration in fat emulsion.
    Anderson RP; Clark DA
    Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-based antifungal agents: a concise overview.
    Arikan S
    Cell Mol Biol Lett; 2002; 7(3):919-22. PubMed ID: 12378276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between liposomal formulations of amphotericin B.
    Adler-Moore JP; Gangneux JP; Pappas PG
    Med Mycol; 2016 Mar; 54(3):223-31. PubMed ID: 26768369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifungal activity against Candida albicans of starch Pickering emulsion with thymol or amphotericin B in suspension and calcium alginate films.
    Cossu A; Wang MS; Chaudhari A; Nitin N
    Int J Pharm; 2015 Sep; 493(1-2):233-42. PubMed ID: 26231107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologically active amphotericin B-calix[4]arene conjugates.
    Paquet V; Zumbuehl A; Carreira EM
    Bioconjug Chem; 2006; 17(6):1460-3. PubMed ID: 17105224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation.
    Zu Y; Sun W; Zhao X; Wang W; Li Y; Ge Y; Liu Y; Wang K
    Eur J Pharm Sci; 2014 Mar; 53():109-17. PubMed ID: 24345795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium phosphate compatibility in 3-in-1 parenteral nutrient admixtures.
    Allwood MC
    Am J Hosp Pharm; 1994 Oct; 51(20):2602-3. PubMed ID: 7847426
    [No Abstract]   [Full Text] [Related]  

  • 29. Structure and toxicity of amphotericin B/triglyceride emulsion formulations.
    Lance MR; Washington C; Davis SS
    J Antimicrob Chemother; 1995 Jul; 36(1):119-28. PubMed ID: 8537259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical "knockout" challenges the amphotericin B channel model.
    Kozmin SA
    Nat Chem Biol; 2008 Jan; 4(1):19-20. PubMed ID: 18084276
    [No Abstract]   [Full Text] [Related]  

  • 31. [Amphotericin B-intralipid 20% combination. In vivo evaluation of its tolerability].
    Débat Zoguéreh D; Poignard P; Sorriaux A; Brouqui P
    Ann Med Interne (Paris); 1997; 148(1):100-2. PubMed ID: 9137701
    [No Abstract]   [Full Text] [Related]  

  • 32. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatal fat embolism following amphotericin B lipid complex injection.
    Tolentino LF; Tsai SF; Witt MD; French SW
    Exp Mol Pathol; 2004 Dec; 77(3):246-8. PubMed ID: 15507243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid-based formulations of amphotericin B.
    Swenson CE; Bolcsak LE; Perkins WR; Janoff AS
    J Antimicrob Chemother; 1995 May; 35(5):709-13. PubMed ID: 7592188
    [No Abstract]   [Full Text] [Related]  

  • 35. Conformational analysis of amphotericin B molecule.
    Silberstein AYa ; Smirnov SL
    Membr Cell Biol; 1997; 10(5):553-63. PubMed ID: 9225259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid formulations of amphotericins: are you a lumper or a splitter?
    Wingard JR
    Clin Infect Dis; 2002 Oct; 35(7):891-5. PubMed ID: 12228829
    [No Abstract]   [Full Text] [Related]  

  • 37. Lipid amphotericin B formulations as comparators in clinical trials.
    Powers JH; Albrecht R
    Clin Infect Dis; 2004 Jan; 38(2):305-6; author reply 306-7. PubMed ID: 14699471
    [No Abstract]   [Full Text] [Related]  

  • 38. Amphotericin B lipid preparations: what are the differences?
    Adler-Moore JP; Proffitt RT
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amphotericin B: is a lipid-formulation gold standard feasible?
    Spellberg B; Witt MD; Beck CK
    Clin Infect Dis; 2004 Jan; 38(2):304-5; author reply 306-7. PubMed ID: 14699470
    [No Abstract]   [Full Text] [Related]  

  • 40. [Amphotericin B and lipids: a new formulation].
    Ordóñez J; García A; Ferrándiz R
    Nutr Hosp; 1994; 9(2):114-5. PubMed ID: 8031949
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.